NYSE$SOLV
Solventum Corporation · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Solventum reported Q1 2026 total net sales of $2.01B (-3% YoY), net income of $13M, and diluted EPS of $0.07.
For the three months ended March 31, 2026, Solventum posted total net sales of $2.01 billion versus $2.07 billion, with net income of $13 million ($0.07 diluted EPS) compared with $137 million ($0.78) when tax benefited prior-year results. Operating income was $81 million; interest expense was $62 million following the spin from 3M.
- Total net sales $2.01B (-3% YoY).
- Net income $13M; diluted EPS $0.07 vs. $0.78.
- Product sales $1.51B; software and rentals $493M.
- Operating income compressed to $81M.
- Separation-related costs and debt service weigh on EPS.
Headline financials
Revenue & EPS history
Solventum · Revenue · Quarterly
$2.01B
Revenue by segment
Solventum · $1.83B total across 3 segments · Q3 2023
- MedSurg$1.18B—64.4%
- Dental Solutions$331M—18.1%
- Health Information Systems$321M—17.5%
Forward guidance
Newly independent medtech discusses portfolio optimization and margin initiatives without long history of public guidance.
Tailwinds
- Cash generation focus post-spin.
- Portfolio diversity across medtech categories.
Headwinds
- Year-over-year earnings decline on lower sales and tax comparison.
- Elevated interest expense.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q1 2026
+0.2%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+2.1%
Avg return
30 days after
42%
5 / 12 earnings
Positive
+8.4%
Q2 2024
Best reaction
-4.7%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.4% | +8.7% | +21.2% | |
| Q4 2025 | -3.7% | -8.5% | -18.4% | |
| Q3 2025 | +7.7% | +11.4% | +28.9% | |
| Q2 2025 | +1.7% | +3.4% | +1.1% | |
| Q1 2025 | +5.5% | +6.8% | +12.3% | |
| Q4 2024 | -4.4% | -6.7% | -10.4% | |
| Q3 2023 | -4.7% | -6.7% | -6.8% | |
| Q3 2024 | -2.3% | -4.6% | -5.6% | |
| Q2 2023 | -1.6% | -1.5% | +12.9% | |
| Q2 2024 | +8.4% | +4.2% | +18.4% | |
| Q1 2023 | -2.6% | -3.7% | -13.0% | |
| Q1 2024 | -4.0% | -2.0% | -15.1% | |
| Q4 2023 | — | — | — | |
| Q4 2022 | — | — | — | |
| Q3 2022 | — | — | — | |
| Q2 2022 | — | — | — | |
| Q1 2022 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro